Evidence map›Paper›PMID 21992606›Full record

ArticleRetrovirology2011

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.

Suha Saleh, Fiona Wightman, Saumya Ramanayake, Marina Alexander, Nitasha Kumar, Gabriela Khoury, Cândida Pereira, Damian Purcell, Paul U Cameron, Sharon R Lewin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Retrovirology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02071095 (Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection), which is not on this map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02071095 phase1 / phase2completednot on this mapstarted 2014, after this paper: background citation

Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection

TypeinterventionalSponsorNina BhardwajRan2014 to 2016Enrolled15ConditionsHIV-1 Infected Adults With Chronic HIV-1 InfectionArmsArm A: Poly-ICLC, Arm B: Normal Saline
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 93 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Transcription of HIV-1 at sites of intact latent provirus integration.bioRxiv : the preprint server for biology · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. CD4mBio · 2020
    Article
  15. Article
  16. Article
  17. Article
  18. Combination Immune Checkpoint Blockade to Reverse HIV Latency.Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Suha SalehDepartment of Medicine, Monash University, Melbourne, VIC, Australia.
Fiona Wightman
Saumya Ramanayake
Marina Alexander
Nitasha Kumar
Gabriela Khoury
Cândida Pereira
Damian Purcell
Paul U Cameron
Sharon R Lewin
Burnet Institute · AUMonash University · AUThe Alfred Hospital · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe recently described that HIV latent infection can be established in vitro following incubation of resting CD4+ T-cells with chemokines that bind to CCR7. The main aim of this study was to fully define the post-integration blocks to virus replication in this model of CCL19-induced HIV latency.

resultsHigh levels of integrated HIV DNA but low production of reverse transcriptase (RT) was found in CCL19-treated CD4+ T-cells infected with either wild type (WT) NL4.3 or single round envelope deleted NL4.3 pseudotyped virus (NL4.3- Δenv). Supernatants from CCL19-treated cells infected with either WT NL4.3 or NL4.3- Δenv did not induce luciferase expression in TZM-bl cells, and there was no expression of intracellular p24. Following infection of CCL19-treated CD4+ T-cells with NL4.3 with enhanced green fluorescent protein (EGFP) inserted into the nef open reading frame (NL4.3- Δnef-EGFP), there was no EGFP expression detected. These data are consistent with non-productive latent infection of CCL19-treated infected CD4+ T-cells. Treatment of cells with phytohemagluttinin (PHA)/IL-2 or CCL19, prior to infection with WT NL4.3, resulted in a mean fold change in unspliced (US) RNA at day 4 compared to day 0 of 21.2 and 1.1 respectively (p = 0.01; n = 5), and the mean expression of multiply spliced (MS) RNA was 56,000, and 5,000 copies/million cells respectively (p = 0.01; n = 5). In CCL19-treated infected CD4+ T-cells, MS-RNA was detected in the nucleus and not in the cytoplasm; in contrast to PHA/IL-2 activated infected cells where MS RNA was detected in both. Virus could be recovered from CCL19-treated infected CD4+ T-cells following mitogen stimulation (with PHA and phorbyl myristate acetate (PMA)) as well as TNFα, IL-7, prostratin and vorinostat.

conclusionsIn this model of CCL19-induced HIV latency, we demonstrate HIV integration without spontaneous production of infectious virus, detection of MS RNA in the nucleus only, and the induction of virus production with multiple activating stimuli. These data are consistent with ex vivo findings from latently infected CD4+ T-cells from patients on combination antiretroviral therapy, and therefore provide further support of this model as an excellent in vitro model of HIV latency.

Indexed as

CD4-Positive T-LymphocytesCell LineCells, CulturedChemokine CCL19env Gene Products, Human Immunodeficiency VirusGene Expression Regulation, ViralHIV-1HIV InfectionsHumansModels, BiologicalVirus IntegrationVirus LatencyVirus ReplicationChemokine CCL19env Gene Products, Human Immunodeficiency Virus

Identifiers

PMID21992606
PMCPMC3215964
OpenAlexW2097473216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.